Retinotech was founded to close the gap in automated glaucoma screening — a condition affecting 80 million people worldwide, most undiagnosed until irreversible vision loss occurs.
Dr. Anna Kowalska and Prof. Michał Wiśniewski begin a collaborative project at Jagiellonian University Medical College and AGH University of Science and Technology, funded by the National Centre for Research and Development (NCBR), to apply deep learning to optic disc analysis in Polish population fundus archives.
Retinotech Sp. z o.o. is incorporated in Kraków with seed funding from SpeedUp Venture Capital Group and a grant from Poland's Intelligent Development programme. Initial team: 6 engineers and 2 clinical advisors.
Multi-centre retrospective study (n=4,218) completed across five Polish ophthalmology departments. Results submitted to Graefe's Archive for Clinical and Experimental Ophthalmology.
Clinical evaluation report and technical documentation drafted for OpticFlow™. Company engaged regulatory consultants to scope EU MDR Class IIa, US FDA, and ISO 13485 pathways.
Research pilots at 12 clinical sites in Poland and Czech Republic. OpticFlow v2.1 released with improved inference speed and Czech/German localisation. Series A led by Inovo Venture Partners (€6.2M).
Ophthalmologist and glaucoma specialist. Former fellow at Moorfields Eye Hospital. MD, PhD (Jagiellonian University).
Professor of Computer Science, AGH. 15+ years in medical image analysis and explainable AI. 40+ peer-reviewed publications.
Former engineering lead at Brainly. Architect of Retinotech's on-premise and cloud inference platform.
12 years in EU medical device regulatory compliance. Previously at Philips Healthcare Poland.
We're hiring ML engineers, regulatory specialists, and clinical affairs managers in Kraków. Hybrid work available.